Company ProfilePremium

TUBIZE (ATTR)

Company Profile Analysis

Ticker: TUB.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
TUBIZE (ATTR) - Company showcase

Year Founded & Workforce

1928

3 Employees

TUBIZE (ATTR) logo

TUBIZE (ATTR) Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

TUBIZE (ATTR) Overview

Financière de Tubize is a single-asset ("mono") holding company. Its only material investment is a 36.29% stake in UCB SA (30 June 2026), the Brussels-headquartered biopharmaceutical group focused on immunology and neurology. Tubize is UCB's reference shareholder. It brings together descendants of UCB founder Emmanuel Janssen and like-minded long-term investors to give UCB a stable, long-horizon anchor shareholder. Tubize has no operating business. Its income statement is UCB's annual dividend less a small cost base, and its balance sheet is the UCB block. Tubize became debt-free in May 2025 and keeps adding to its UCB stake in small increments. It pays out roughly half of its profit as a progressive dividend. Since 2025 its board has been professionalised around biopharma expertise under independent chair Bruno Holthof. For investors, TUB is a leveraged-free, discounted proxy for UCB. The holding discount is the key valuation variable.


Company's own characterisation. Across its regulated releases and corporate descriptions, Tubize presents itself as the reference shareholder of UCB. It groups family shareholders descended from founder Emmanuel Janssen with others who share their long-term view, and it aims to give UCB the stability it needs to invest in new medicines for patients with severe diseases (World Economic Forum organisation profile; company descriptions on Lightyear).

What the company does. Tubize owns and manages one asset: about 70.6 million UCB shares (derived: €102.3M dividend received in 2026 ÷ €1.45 per UCB share). Its activities are:

  1. Shareholder stewardship. It is represented on UCB's board and audit committee. Tubize's H1 2026 report states that its board keeps informed of UCB's activities and management through these representatives. Stefaan Heylen joined the UCB board in March 2024 as a Tubize representative.

  2. Capital allocation. It reinvests part of the UCB dividend in additional UCB shares (24,487 in 2025; 15,783 in H1 2026). It repays acquisition debt (fully repaid May 2025). It distributes dividends to its own shareholders (€48.1M paid in 2026).

  3. Governance of the family concert. It manages relations with family shareholders. This role was assigned to Vice-Chair Cyril Janssen in August 2025.

Business and revenue model.

Value-chain position. Tubize sits at the top of the ownership chain of a fully integrated biopharma company. UCB discovers, develops, manufactures and commercialises medicines in immunology (Bimzelx, Cimzia, Evenity via Amgen partnership) and neurology/rare disease (Briviact, Vimpat, Fintepla, Rystiggo, Zilbrysq, Kygevvi). Tubize itself has no customers. Economically, its "end-market" is UCB's: specialty biopharma, mainly sold in the United States, then Europe and international markets.

Independent characterisation. Tubize is best understood as a closed-end, permanently capitalised vehicle for UCB equity. Its economic drivers are:

  • the UCB share price, which drives net asset value (NAV);

  • UCB's dividend, which drives Tubize earnings and its own dividend;

  • the market discount applied to Tubize versus look-through NAV (about 47% at mid-October 2026, derived).

Unlike Belgian peers Sofina, GBL or Ackermans & van Haaren, Tubize has no diversification. Its revenue and capital returns are a lagged, damped derivative of UCB's capital-return policy. UCB pays a modest dividend (€1.45/share for FY2025), so Tubize's earnings yield on market value is low. Its trailing P/E is structurally high, around 83x at €173.10 (derived). Earnings multiples are therefore of limited use, and NAV discount analysis is the relevant valuation framework.

Strategy

Stated strategy (paraphrased from company releases).

  1. Act as UCB's long-term, stable reference shareholder, keeping a stake of about 36%.

  2. Support UCB's growth and its investment in new medicines.

  3. Strengthen biopharma expertise on the Tubize board so it can be an informed, constructive owner.

  4. Promote a sustainable biopharma ecosystem in Belgium, the UK and other geographies relevant to UCB (chair's statement, 29 Apr 2025).

  5. Keep the balance sheet strong. Quartr's summary of Tubize's 2025 annual presentation references strategic reserves supporting UCB while maintaining the 36% stake.

Initiatives in the last 24 months

Cost programmes: none disclosed. The cost base is about €2–3M a year.

ESG commitments: none at Tubize level.

Medium-term financial targets: none published. Tubize gives no guidance. Its H1 2026 outlook only states that it will stay attentive to geopolitical developments and their possible effect on UCB and on its own results.

Products & Services

Tubize has no products or services of its own. Its "portfolio" is one listed equity stake. For completeness, the economic exposure is catalogued through UCB's commercial portfolio. Figures are UCB-reported.

5a. Tubize's direct offering

5b. Look-through UCB portfolio (principal brands)

Named pipeline bets (look-through): glovadalen (UCB0022, Parkinson's, positive Phase 2a); bepranemab (Alzheimer's, Fast Track); galvokimig (atopic dermatitis, Phase 2b); bimekizumab in palmoplantar pustulosis (Phase 3); STACCATO alprazolam (prolonged seizures, headline results expected 2026). Source: UCB FY2025 results, 26 Feb 2026.

Product Portfolio

OfferingDescriptionTarget "customer"Pricing

TUB ordinary share

Listed share giving look-through exposure to about 1.59 UCB shares per TUB share (derived: 70.55M ÷ 44.51M)

Long-term investors, family holders, index funds (e.g., iShares EURO STOXX Small; FTSE All-World constituents)

Market price; annual gross dividend €1.08 (FY2025)

BrandMolecule / classTherapeutic areaStatus / data pointSource

BIMZELX

bimekizumab, IL-17A/IL-17F inhibitor

Psoriasis, psoriatic arthritis, axial SpA, hidradenitis suppurativa

Net sales €2.23bn in FY2025 (more than tripled); €1.528bn in H1 2026; peak-sales guidance raised to at least €7bn; protection to 2037; BE BOLD was the fourth head-to-head superiority study

UCB FY2025 and H1 2026 releases; H1 2026 call

EVENITY

romosozumab (with Amgen)

Osteoporosis

One of five "growth drivers"

UCB FY2025 release

FINTEPLA

fenfluramine

Rare epilepsies (Dravet, LGS; CDKL5 Phase 3 GEMZ positive Jun 2025)

Next major loss of exclusivity flagged for 2033

UCB H1 2025 / H1 2026 materials

RYSTIGGO

rozanolixizumab, FcRn inhibitor

Generalised myasthenia gravis; ocular MG Phase 3 started Q2 2026

Growth driver

UCB H1 2026 release

ZILBRYSQ

zilucoplan, C5 inhibitor

Generalised myasthenia gravis

Growth driver

UCB FY2025 release

KYGEVVI

doxecitine and doxribtimine

Thymidine kinase 2 deficiency (TK2d)

Approved in US; EU positive opinion

UCB FY2025 release

BRIVIACT

brivaracetam

Epilepsy

€758M net sales in FY2025 (+11%); US exclusivity ended Feb 2026, EU Aug 2026

UCB FY2025 (Investing.com)

CIMZIA

certolizumab pegol

Immunology

Price erosion flagged

UCB H1 2025 summary

VIMPAT / KEPPRA

lacosamide / levetiracetam

Epilepsy (mature, genericised)

Mature brands

UCB reports

Financial Narrative

Tubize reports under Belgian GAAP at statutory level and publishes annual and half-year financial reports. Ratios are derived.

6a. Income statement

Sources: TipRanks (FY2021–FY2024 line items); Tubize releases (FY2023–FY2025 profit and DPS); Beursgenoten (FY2025 operating result about -€3M); EPS FY2025 derived as 93.2 ÷ 44.51.

Note on FY2020. Net income was €260.5M (EPS €5.85, TipRanks). This is a non-recurring outlier and is excluded from trend analysis.

Margins. Gross, operating, EBITDA and net margins are not meaningful because operating revenue is about zero. A useful substitute is the profit-to-dividend-received conversion. In H1 2026, profit of €100.8M on €102.3M received is about 98.5% (derived). Corporate costs and interest absorb only about 1–3% of gross income.

Revenue CAGR. Not meaningful. The CAGR of net income FY2021–FY2025 is 2.75% (derived).

6b. Half-year income (seasonality: UCB pays its dividend in Q2)

Sources: Tubize H1 2025 and H1 2026 releases; Dutch H1 2026 report (interest). The H1 2024 UCB DPS of €1.36 is UCB's FY2023 dividend, implied from the 2.2% increase to €1.39.

Full-year profit falls below H1 profit (FY2025 €93.2M versus H1 2025 €95.6M). This is because H2 carries only costs and no dividend income.

6c. Balance sheet

Sources: Tubize releases (debt, FY2025 equity, solvency, purchases). Equity for FY2022–FY2024 is derived by rolling FY2025 equity back by net profit less dividends paid (2023 €38.3M, 2024 €43.2M, 2025 €46.3M). Treat it as indicative.

H1 2026: equity €1,986.3M, solvency ratio 99.98%, no bank debt (H1 2026 report summary, Quartr).

Cash and equivalents: small working balance. Exact figure n/d in sources reviewed.

Goodwill and intangibles: nil.

Working capital: minimal. Lightyear reports a TTM current ratio of about 3.2x.

Net debt: about nil or slightly negative from mid-2025.

Short/long-term debt split: short-term bank lines historically. The lines were secured by pledges over UCB shares (pledge over 95,000 UCB shares through 30 June 2026 per the Dutch H1 2026 report).

6d. Cash flow (holding-level, derived from disclosed items)

Sources: Tubize releases. Dividends paid are derived as prior-year DPS × 44.51M shares. FY2025 dividends paid matches the €46.3M disclosed in the H1 2025 report. The 2023 debt drawdown financed the 1.04M-share UCB purchase.

  • 2026 year to date: €102.3M received, €48.1M paid, €4.05M of UCB shares bought.

  • Share buybacks: none disclosed.

6e. Ratios

All ratios derived. Lightyear independently shows TTM ROE of 5.00%.

ROA is about equal to ROE given negligible liabilities. ROIC, interest coverage, asset turnover and cash conversion cycle are not meaningful for a holding with no operations. Interest coverage moved to "infinite" once interest fell to nil in H1 2026.

Trend commentary. Three phases stand out:

  1. Deleveraging, 2017–2022. Debt fell from €192M (end-2017) to €47.8M (end-2022) while the dividend rose.

  2. Opportunistic re-leveraging, 2023. Tubize bought over 1 million UCB shares during UCB's 2023 share-price trough. This raised the stake by 54bp to 36.24% and lifted debt to €79.2M. In hindsight it was a well-timed move, because UCB's share price subsequently multiplied on the Bimzelx launch.

  3. Rapid deleveraging to zero, 2024–2025. Purchases were scaled back to token amounts (about €4M a year).

Profit growth is mechanical: roughly UCB DPS growth plus the stake increment, minus interest. The board has prioritised dividend growth (+12.8%, +7.2%, +3.85%) over large stake increases since 2024. Dividend growth decelerated in line with UCB's own 2.2% and 4.3% DPS increases.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment and Segment Margins & Growth (%)

MetricFY2021FY2022FY2023FY2024FY2025

Net profit (EUR Mn)

83.685.288.290.193.2

Profit YoY growth (%)

—1.93.52.23.5

Contribution to total income (%)

100100100100100

UCB stake at year end (%)

—35.7036.2436.2736.28

Revenue by Segment and Per-Share Data

MetricFY2024FY2025

UCB revenue (EUR Mn)

6,1507,740

UCB net sales (EUR Mn)

—7,390

UCB adjusted EBITDA (EUR Mn)

—2,640

UCB core EPS (EUR)

—9.99

UCB dividend per share (EUR)

1.391.45

Revenue by Segment

Metric (EUR Mn)H1 2025H1 2026

UCB revenue

3,4874,270

UCB adjusted EBITDA

1,0331,740

Bimzelx net sales

7991,528

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue, operating (EUR Mn)

0.000.010.000.010.00

Operating result, holding costs (EUR Mn)

-1.54-1.82-2.14-2.24-3.0

Financial income, net of interest (EUR Mn)

85.1486.9990.3092.34—

Pre-tax income (EUR Mn)

83.685.288.290.193.2

Net income (EUR Mn)

83.685.288.290.193.2

EPS basic, EUR

1.881.911.982.022.09

EPS diluted, EUR

1.881.911.982.022.09

Gross dividend per share, EUR

—0.860.971.041.08

DPS growth (%)

——12.87.23.85

Payout ratio, declared DPS / EPS (%)

—45.049.051.551.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Dividends & Capital Returns and Per-Share Data

MetricH1 2024H1 2025H1 2026

H1 profit (EUR Mn)

92.995.6100.8

UCB dividend received (EUR Mn)

—98.1102.3

UCB DPS received (EUR)

1.361.391.45

Interest expense (EUR Mn)

—0.7190.0

Balance Sheet and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025

Bank borrowings (EUR Mn)

47.879.241.30.0

Shareholders' equity (EUR Mn)

1,741.91,791.81,838.71,885.6

Solvency ratio (%)

———97.49

UCB shares acquired in year (thousand)

—1,043.953.724.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Dividends & Capital Returns

Metric (EUR Mn)FY2023FY2024FY2025

UCB dividend received

——98.1

Dividends paid to TUB shareholders

38.343.246.3

UCB share purchases (capex equivalent)

——4.4

Net bank debt repayment / (drawdown)

-31.437.941.3

Margin Analysis (%) and Financial Ratios (x)

MetricFY2023FY2024FY2025

ROE on average equity (%)

5.05.05.0

Debt / equity (%)

4.42.20.0

Net debt / profit (x)

0.900.460.00

Revenue by Region (%)

RegionFY2023FY2024FY2025

Belgium, Tubize dividend income (% of total)

100100100

All other regions, Tubize (% of total)

000

Share Price & Returns

DateTUB close (EUR)Source

3 Oct 2025

≈218.00

Trivano (KBC note)

31 Dec 2025

≈208.9

Derived from €9.30bn market cap ÷ 44.51M

30 Jun 2026

231.00

H1 2026 report

8 Jul 2026

214.80

EODData

6 Aug 2026

193.30

Trivano

24 Aug 2026

188.40

Trivano

28 Sep 2026

179.40

Trivano

12 Oct 2026

173.10

Trivano

Market Valuation

MetricFY2025

Market cap at year end (EUR Bn)

9.30

Valuation Multiples

MultipleTUBComment

Trailing P/E (FY2025 EPS €2.09)

≈82.8x

Structurally high for a dividend-receiving holding

P/B (H1 2026 equity €1,986.3M)

≈3.9x

Book carries UCB below market value

Dividend yield (€1.08 gross)

≈0.62%

—

Discount to look-through NAV

≈47%

—

UCB P/E (look-through)

≈17.7–17.8x

Ad-hoc News, Oct 2026

Analyst Ratings & Targets

BrokerDateRatingTarget (EUR)

Degroof Petercam

24 Aug 2026

Buy (upgraded from Hold)

286

KBC Securities

3 Oct 2025

Accumulate (downgraded from Buy)

217

Consensus (Trivano)

Aug 2026

—

251.50 average

Consensus (Stockopedia, earlier)

—

Hold

230.50

Per-Share Data

MetricFY2018FY2022FY2023FY2024FY2025

Gross DPS (EUR)

0.560.860.971.041.08

Analyst Conclusions

Management guidance. None. Tubize's 2026 income is effectively locked in. The FY2025 UCB dividend of €1.45 produced €102.3M, already received. H1 2026 profit was €100.8M, so FY2026 profit will likely land near €98M (H1 less H2 costs; analyst inference, not guidance). That supports another modest dividend increase in 2027 if UCB raises its FY2026 dividend.

Look-through consensus drivers. UCB guides FY2026 revenue growth in the low-to-mid-teens and adjusted EBITDA growth in the mid-teens to low-20s at constant exchange rates (H1 2026 call). Bimzelx peak sales are guided at least €7bn. Broker targets on UCB range from €260 (Barclays, Hold) to €304 (ING), against about €205 currently.

Bull case

  1. Double leverage to UCB recovery. If UCB re-rates toward the €260–304 broker range (+27–48%) and the TUB discount stays constant, TUB rises proportionally. If the discount also narrows from about 47% toward 35–40%, the upside compounds.

  2. Dividend acceleration. UCB's earnings are inflecting (H1 2026 EBITDA +68%, core EPS €6.84). A step-up in UCB's payout would flow almost one-for-one to Tubize's profit and dividend, given about 98% conversion.

  3. Balance-sheet optionality. Tubize is debt-free and has shown it can buy aggressively on dips (2023). It can accrete UCB shares cheaply while UCB trades about 30% below its high.

Bear case

  1. Concentration risk materialising. Briviact loss of exclusivity in 2026, US Bimzelx net-price pressure and rising R&D (about 25% of sales) could cap UCB's share price. The September–October 2026 derating shows the sensitivity.

  2. Sticky or widening discount. Family control, a 0.6% yield, no buybacks and placement overhang (November 2025) give investors little reason to close the 47% gap.

  3. Low cash return on market value. Profit growth of about 3% a year and a P/E above 80x leave TUB reliant entirely on UCB price appreciation for returns.

Key catalysts and monitorables (next 12 months)

Analyst verdict. Financière de Tubize is a clean, almost frictionless vehicle for UCB equity. It now carries no debt, a cost base under €3M, a 36.29% stake and a board that has been deliberately upgraded with biopharma expertise since 2025. Its reported numbers are a slow-moving reflection of UCB's conservative dividend policy: profit has risen from €83.6M in FY2021 to €93.2M in FY2025, and the dividend from €0.86 to €1.08 per share. These numbers say little about the value being created underneath. That value sits in UCB's transformation into an immunology leader. Bimzelx sales doubled to €1.53bn in H1 2026, UCB's adjusted EBITDA margin reached 40.7%, and management guides peak Bimzelx sales of at least €7bn with exclusivity to 2037.

The investment case therefore rests on two variables: the UCB share price and the Tubize discount. At €173.10, TUB implies a look-through NAV of about €325 per share, a discount of about 47%. That discount sits at the wide end of what family-controlled Belgian holdings typically carry. It coincides with UCB itself trading roughly 30% below its 52-week high on Briviact loss of exclusivity and US pricing concerns. This double compression is what drove Degroof Petercam's August 2026 upgrade to Buy (€286 target).

The counterweights are real. Tubize offers no buybacks, a sub-1% yield, thin liquidity and visible family-branch selling (the ~€172M placement in November 2025). Its fortunes are wholly hostage to a single biopharma company. It is unsuitable for income or diversification mandates. Stance: constructive, discount-driven; position sizing should treat TUB as a UCB position with added discount volatility.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenureCompensation

Eric Nys

Managing Director / CEO

Active at least since 2023 (AGM correspondent in 2023 convocation)

€201.0k per Yahoo Finance (year and composition n/d)

Anne Sophie Pijcke

General Manager / Director

Long-standing; IR contact on FY2018 release

€37k per Yahoo Finance (year n/d)

Anne Keup

Management board member (per ShareCompany/Beursgenoten)

——

Board of Directors — Prof. Dr Bruno Holthof

NameRoleNotes

Prof. Dr Bruno Holthof

Chair (since 25 Apr 2025)

Previously independent director. Aims to strengthen biopharma expertise and support a biopharma ecosystem in Belgium, the UK and UCB's other key geographies (29 Apr 2025 release).

Cyril Janssen

Vice-Chair (since 1 Aug 2025); via Nikita SRL

Re-appointed April 2025 to the 2029 AGM. Manages family-shareholder relations. Born 1971. Co-controls Financière Eric Janssen.

Iris Löw-Friedrich

Director (since Sep 2025)

MD, PhD, internist. Former member of the Boehringer Ingelheim Board of Managing Directors (Jan 2020–Sep 2024, Human Pharma). Boards: Fresenius, Sobi, Evotec; Munich Re supervisory board. Born 1960.

Eric Cornut

Director (profile published for 24 Apr 2026 AGM)

Former pharma executive; detailed bio n/d in sources reviewed.

Evelyn du Monceau

Director

Family director; born 1950; renewal proposed 2023 AGM.

Charles-Antoine Janssen

Director

Family director; born 1971.

Cédric van Rijckevorsel

Director

Family director.

Cynthia Favre d'Echallens

Director

—

Tanguy du Monceau

Director

Family director.

Sandrine Flory

Director

—

Carinne (Knoche-)Brouillon

Former director

Appointed Sep 2025; resigned effective 24 Apr 2026.

Board & Management Changes

DateChangeContext

25 Apr 2025

Gaëtan Hannecart leaves; Bruno Holthof becomes chair

Generational handover and professionalisation

1 Aug 2025

Cyril Janssen named Vice-Chair

Family-relations role

Sep 2025

Löw-Friedrich and Brouillon appointed

Biopharma expertise

24 Apr 2026

Brouillon resigns; Eric Cornut proposed

Board refresh

Mar 2024

Stefaan Heylen joins UCB board for Tubize

Reinforced representation at UCB

Major Shareholders

HolderStake (%)

Financière Eric Janssen SPRL

19.15

Daniel Janssen

13.21

Altai Invest SA

11.16

Barnfin SA

8.80

Top-4 combined

52.32

Competitive Landscape

Key Competitors

PeerProfileRelative positioning versus Tubize

Solvac

Family duo-holding (Solvay, Syensqo)

Also a family-controlled holding at a deep discount; press noted it underperformed its underlying assets in 2025 while Tubize re-rated

Sofina

Diversified, growth/private-equity focused

Diversified, actively managed

Groupe Bruxelles Lambert (GBL)

Diversified listed and private holding

Larger, buybacks, active rotation

Ackermans & van Haaren

Diversified (marine, banking, real estate)

Operating-company mix

Gimv

Private-equity investor

Different asset class

KBC Ancora / Cera

Mono-holding of KBC shares

Closest structural analogue (mono-holding)

Brederode

Listed PE fund-of-funds holding

Discount vehicle

Solvac / Tubize-type family holdings

Belgian control vehicles

Same discount drivers

Key Competitors by Competitor

CompetitorCompeting franchiseArena

AbbVie

Skyrizi (IL-23), Humira

Psoriasis, PsA, HS

Johnson & Johnson

Tremfya, Stelara

Psoriasis, PsA

Novartis

Cosentyx (IL-17A)

Psoriasis, PsA, axSpA, HS

Eli Lilly

Taltz (IL-17A)

Psoriasis, PsA, axSpA

Amgen

Otezla; also Evenity partner

Psoriasis (oral), osteoporosis

argenx

Vyvgart (FcRn)

Myasthenia gravis versus Rystiggo

AstraZeneca / Alexion

Ultomiris, Soliris (C5)

Myasthenia gravis versus Zilbrysq

Jazz Pharmaceuticals

Epidiolex

Rare epilepsies versus Fintepla

Eisai, Sunovion and generics

Antiepileptics

Epilepsy (post-Briviact LOE)

Peer Comparison FY2025

CompanyRevenue FY2024Revenue growth FY2025Adj. EBITDA marginR&D intensity

UCB

€6.15bn

+26% (to €7.74bn)

34% reported (31.4% underlying) FY2025

About 25% of net sales (FY2026 guide)

Company Snapshot

3

Employees

1928

Founded

Brussels, Belgium

Headquarters

SWOT Analysis

Strengths

  • Debt-free since May 2025. Solvency ratio 99.98% at 30 Jun 2026 (H1 2026 report).
  • Stable 36.29% reference stake in UCB, built steadily from 35.70% at end-2022.
  • Exceptionally lean: H1 2026 profit of €100.8M was about 98.5% of the €102.3M dividend received (derived).
  • Progressive dividend: €0.86 → €0.97 → €1.04 → €1.08 for FY2022–FY2025.
  • Strengthened board biopharma expertise. A former Boehringer Ingelheim board member joined in September 2025.
  • Underlying asset in strong growth: UCB H1 2026 revenue +22% and Bimzelx sales +91% (UCB H1 2026 report).

Weaknesses

  • One-asset concentration: 100% of income from UCB.
  • Trailing P/E around 83x and yield around 0.6% at €173.10 (derived). This makes TUB unattractive to income or earnings-screen investors.
  • Persistent discount to NAV, about 47% (derived, mid-October 2026).
  • Thin liquidity: average volume about 24k shares a day (Lightyear).
  • Limited disclosure: no committee details, auditor name or employee data in readily available sources; no guidance.
  • Family-majority board, with a top-4 holder block of 52.32% (ShareCompany). This limits minority influence.

Opportunities

  • UCB guidance upgrade and Bimzelx peak sales of at least €7bn could drive UCB's dividend growth higher over time.
  • Discount narrowing toward historical or peer levels. Degroof Petercam's €286 target versus the €173 price is a +65% case.
  • Index inclusion (FTSE All-World) broadens passive ownership.
  • With a debt-free balance sheet, Tubize can buy UCB shares opportunistically on dips, as it did in 2023.
  • UCB shares about 30% below their 52-week high offer a cheap accretion opportunity.
  • Its role in a Belgian/UK biopharma ecosystem (chair's mandate) could support governance credibility.

Threats

  • UCB-specific risks: Briviact loss of exclusivity in 2026; US Bimzelx net-price pressure; pipeline failures.
  • UCB share-price volatility: the 52-week low/high spread was 32% (€197.45 versus €289.50).
  • Secondary-placement overhang from family branches (~€172M block placed in November 2025).
  • US drug-pricing policy and tariffs affecting UCB's US-heavy revenue base.
  • Belgian tax changes on dividends and capital gains could alter holding economics. Belgian withholding is 30%, as implied by the gross €1.08 versus net €0.76.
  • Geopolitical shocks. These were noted, with no significant impact so far, in the H1 2026 report.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
22 Mar 2025FY2024 annual report: profit €90.1M (+2.2%); debt €41.3M; €1.04 dividend proposedBase-year confirmation
26 Mar 2025Convening of AGM/EGM of 25 Apr 2025Governance
25 Apr 2025AGM approves €1.04 dividend; Nikita SRL (Cyril Janssen) re-appointed to 2029Family continuity
25 Apr 2025Bruno Holthof elected chair after Hannecart's departure (announced 29 Apr)Professionalisation
30 Apr / 5 May 2025Ex-date and payment of €1.04 dividend (coupon 20)Capital return
May 2025Bank debt fully repaidDebt-free holding
31 Jul 2025UCB H1 2025: revenue €3.49bn (+25%); FY2025 guidance raised to at least €7bnLook-through upgrade
1 Aug 2025Cyril Janssen appointed Vice-ChairGovernance
2 Aug 2025Tubize H1 2025: profit €95.6M (+2.8%); UCB dividend €98.1M; zero debtResults
4 Aug 2025Belgian press: debt-free Tubize gets higher price targetsSentiment
~23–24 Sep 2025EGM appoints Iris Löw-Friedrich and Carinne BrouillonBiopharma expertise
3 Oct 2025KBC Securities cuts TUB to Accumulate; target raised from €186 to €217Valuation call
13 Oct 2025Degroof Petercam cuts TUB to Hold, raises targetValuation call
~4 Nov 2025~€172M private placement of existing TUB shares via Degroof Petercam; shares pressuredSupply overhang; free-float increase
30 Dec 2025Press notes Tubize's modest re-rating during 2025Sentiment
Feb 2026Briviact US exclusivity expiresLook-through headwind
26 Feb 2026UCB FY2025: revenue €7.74bn (+26%); adjusted EBITDA €2.64bn; DPS €1.45 (+4%)Sets Tubize 2026 income
2026 (date n/d)TUB added to FTSE All-World IndexPassive demand
21 Mar 2026Tubize FY2025 annual report: profit €93.2M (+3.5%); €1.08 dividend proposed; new HQ addressResults
25 Mar 2026Convening of AGM of 24 Apr 2026Governance
24 Apr 2026AGM approves €1.08 dividend; Brouillon resigns; Eric Cornut profile presentedBoard refresh
7 / 8 / 11 May 2026Ex-date, record date and payment of €1.08 (coupon 21)€48.1M distributed
30 Jun 2026TUB closes at €231; market cap €10.28bnPeak valuation zone
30 Jul 2026UCB H1 2026: revenue €4.27bn (+22%); adjusted EBITDA margin 40.7%; guidance raised; Bimzelx peak at least €7bnStrong fundamentals
1 Aug 2026 (published 7 Aug)Tubize H1 2026: profit €100.8M (+5.4%); stake 36.29%; equity €1,986.3MResults
Aug 2026Briviact EU exclusivity expiresLook-through headwind
24 Aug 2026Degroof Petercam upgrades TUB to Buy, target €286Discount-driven call
4 Sep 2026UCB falls 4.6% in one session; continued derating through SeptemberNAV pressure
2 Oct 2026Barclays keeps Hold on UCB, target €260Look-through sentiment
10 Oct 2026UCB dedicates US Georgia campusLook-through capacity
12 Oct 2026TUB closes at €173.10 (+1.8%), about 25% below its 30 Jun levelCurrent valuation
~13 Oct 2026ING sets UCB target at €304Look-through upside case

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Revenue by Segment (FY2024–FY2025): UCB revenue rose from EUR 6,150 Mn in FY2024 to EUR 7,740 Mn in FY2025.
TUBIZE (ATTR) — Revenue by Segment (FY2024–FY2025)
Series (EUR Mn)FY2024FY2025
UCB revenue6,1507,740
UCB net sales—7,390
UCB adjusted EBITDA—2,640

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Financière de Tubize regulated releases: Annual Report 2025 (21 Mar 2026) · Half-Year Report 2026 (1 Aug 2026, distributed 7 Aug 2026, GlobeNewswire) · Half-Year Report 2025 (2 Aug 2025) · Annual Report 2024 (22 Mar 2025) · Annual Report 2023 (16 Mar 2024) · Annual Financial Report 2018 (28 Feb 2019); dividend approvals (25 Apr 2025, 24 Apr 2026); board releases (29 Apr 2025; 24 Sep 2025); convening notices (2023, 2025, 2026). Dutch full H1 2026 report hosted by VFB.
  2. UCB: Full-Year Report 2025 (26 Feb 2026) · Half-Year Report 2026 (30 Jul 2026) and earnings-call transcript · Half-Year Report 2025 (31 Jul 2025); 2008 transparency notification.
  3. Market data: Quartr (H1 2026 summary) · TipRanks (income statement) · Trivano/De Tijd (price, broker notes, placement) · MarketScreener (news headlines) · Ad-hoc News (UCB price, October 2026) · Investing.com (UCB history, FY2025 summary) · EODData · Lightyear · Parqet; justETF · Simply Wall St · Beursgenoten/ShareCompany (board, shareholders) · Yahoo Finance (management pay) · ZBW/HWWA Press Archive and BCC Research (history).

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.